Pre-made Cergutuzumab benchmark antibody ( Whole mAb Fusion, anti-CEACAM5/CD66e therapeutic antibody, Anti-CEA Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Cergutuzumab biosimilar, Whole mAb Fusion, Anti-CEACAM5/CD66e Antibody: Anti-CEA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
A recombinant fusion protein comprised of cergutuzumab, a genetically engineered human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against carcinoembryonic antigen (CEA, CEACAM5, CD66e), linked to amunaleukin, an engineered, mutated variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities.
| Products Name (INN Index) | Pre-Made Cergutuzumab biosimilar, Whole mAb Fusion, Anti-CEACAM5/CD66e Antibody: Anti-CEA therapeutic antibody |
|---|---|
| INN Name | Cergutuzumab |
| Target | CEACAM5 |
| Format | Whole mAb Fusion |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Roche |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CEACAM5/CD66e |
| Package |
